Scientists have developed statistical models to predict which drug is best for a patient based on a person’s DNA. In the latest issue of Pharma Technology Focus we find out how this method could help doctors tailor treatments to the individual needs of specific patients.
Go deeper with GlobalData
We also explore breakthroughs in malaria research and catch up with a campaign to eliminate river blindness in Africa and Latin America after the Colombian Government declared that it had eradicated the disease.
Moreover, we investigate how changes to GMP guidelines in Europe will affect contract manufacturers and their customers, look at the challenges the cold chain process faces in emerging markets and take a look at upcoming US and EU regulations which are expected to usher in a new era of manufacturing and distribution compliance in the battle against counterfeits.
In this issue
The personal touch
Personalised medicine is one of the biggest advancements for decades, but the revolution is only just beginning. Pharma Technology Focus finds out more from Dr James Broach of Penn State University’s Institute of Personalised Medicines.
Click here to read the full article.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEliminating malaria
On one side of the war zone malaria continues to adapt, while on the other side research is intensifying as scientists work tirelessly towards the goal of total elimination.
Click here to read the full article.
Victory against river blindness
The Colombian government recently announced that it had eradicated onchocerciasis, known as river blindness. We look at how the country has achieved this and what can be done elsewhere.
Click here to read the full article.
Change is the only constant
Recent changes to GMP guidelines across Europe have implications for contract manufacturing organisations and their customers. Pharma Technology Focus learns more from Kim Steffensen of Novo Nordisk.
Click here to read the full article.
Coming in from the cold
The cold chain faces many challenges, and where infrastructure is less established, these become harder to overcome. We talk to Allergan‘s Henryk Junker about managing the process in emerging markets.
Click here to read the full article.
Track and trace
EU and US regulators are initiating a new era of compliance to improve safety and fight counterfeit drugs. We ask if it is a valuable new standard or an unnecessary burden.
Click here to read the full article.
Next issue
Bioelectric medicine could become a reality sooner than expected, thanks to an ambitious plan launched by GSK. We find out how nano-scale devices could harness the electrical language of the human body and explore the technology’s future potential.
We also find out how the DNA patent law will affect pharmaceutical research, ask how new regulations for elemental impurity analysis will affect the industry, and investigate the often controversial decision-making process behind the approval or rejection of cancer treatments in the UK.
Moreover, we explore the ethics of advertising drugs directly to the consumer in the light of a recent study which found a large number of pharmaceutical advertisements to contain potentially misleading claims.
Subscribe for free to get each future issue of Pharma Technology Focus delivered directly to your inbox.
Digital Magazine FAQ
The digital magazine is viewable on any computer with Flash Player installed. It is also viewable on mobile devices, iPhones and iPads, although some features and videos may be disabled.
View the archive of back issues.
